Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US, but expects the release of new drugs and restructuring initiatives will boost the company's financial performance.
Chief executive Scott Richards says the company's first half is expected to be "soft" but that a range of initiatives is already yielding benefits.
